Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
Holding RGNX?
Track your performance easily
RGNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.49 - $28.80
Previous Close$12.95
Volume605.18K
Average Volume (3M)549.78K
Market Cap
$640.03M
Enterprise Value$435.21M
Total Cash (Recent Filing)$290.36M
Total Debt (Recent Filing)$85.54M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 06, 2024EPS Estimate
-$1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.27
Shares Outstanding49,423,188
10 Day Avg. Volume456,616
30 Day Avg. Volume549,779
Standard Deviation0.17
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.78
Price to Sales (P/S)7.19
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.89
Enterprise Value/Gross Profit8.21
Enterprise Value/Ebitda-1.99
Forecast
1Y Price Target
$39.33Price Target Upside213.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
RegenXBio News
PremiumCompany Announcements
RegenXBio Appoints New EVP and CFO Amidst Key Developments
PremiumCompany Announcements
RegenXBio Grants RSUs to Executives Amidst Leadership TransitionBulls Say, Bears Say
Bulls Say
Financial PerformanceREGENXBIO reported lower than expected net loss and is on track for RGX-121 BLA filing under the accelerated approval pathway for potential one-time gene therapy.
Pipeline ProgressInitial biomarker data from the AFFINITY DUCHENNE trial for RGX-202 shows well-tolerance and encouraging increases in microdystrophin expression.
Regulatory ApprovalThe imminent filing and anticipated approval of RGX-121 for MPS II (Hunter syndrome) provide near-term regulatory catalysts and a commercial product with a small but well-identified opportunity.
Bears Say
Competitive LandscapeGrowing competitive wAMD landscape with recent entrants showing extended duration and meaningful reductions in injection burden.
Dose ResponseThere is a lack of dose response making it unclear what dose might be brought forward.
EfficacyThe update raised questions around the cohort 6 efficacy results which were not provided separately despite the additional anti-VEGF run-in injections given to these patients.
---
Ownership Overview
8.94% Insiders
21.53% Mutual Funds
52.99% Other Institutional Investors
16.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $10.49 and its highest was $28.80 in the past 12 months.
What is RegenXBio’s market cap?
Currently, no data Available
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Aug 01, 2024. The company reported -$1.05 earnings per share for the quarter, beating the consensus estimate of -$1.291 by $0.241.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -$1.12.
How many shares outstanding does RegenXBio have?
RegenXBio has 49,423,187 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.05 in its last earnings report, beating expectations of -$1.291. Following the earnings report the stock price went down -2.029%.
Which hedge fund is a major shareholder of RegenXBio?
Among the largest hedge funds holding RegenXBio’s share is Moore Capital Management LP. It holds RegenXBio’s shares valued at 1M.
---
RegenXBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.33 (213.89% Upside)
$39.33 (213.89% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 34.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.16%
12-Months-Change
Fundamentals
Return on Equity
-63.94%
Trailing 12-Months
Asset Growth
-16.57%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
---
RGNX Earnings Call
Q2 2024
0:00 / 0:00
---
RGNX Stock 12 Month Forecast
Average Price Target
$39.33
▲(213.89% Upside)
Technical Analysis
Best Analysts Covering RGNX
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-9.67%
reiterated a buy rating 2 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -9.67% per trade.
---